Hunan Er-Kang Pharmaceutical Valuation

Q: What is the Fair Price of 300267 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

300267 (CN¥3) is trading below our estimate of [[fair value]] (CN¥7.58)

Is 300267 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300267 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300267 (CN¥3) is trading below our estimate of fair value (CN¥7.58)

Significantly Below Fair Value: 300267 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300267?

Key metric: As 300267 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300267. This is calculated by dividing 300267's market cap by their current revenue.
What is 300267's PS Ratio?
PS Ratio	5.2x
Sales	CN¥1.19b
Market Cap	CN¥6.19b

300267 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.9x
Enterprise Value/EBITDA	-723.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 300267's PS Ratio compare to its peers?

The above table shows the PS ratio for 300267 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.6x
000813 Dezhan Healthcare	12.9x	n/a	CN¥6.7b
603718 Shanghai Hile Bio-Technology	24.5x	n/a	CN¥5.4b
000566 Hainan Haiyao	6.5x	n/a	CN¥6.7b
000989 Jiuzhitang	2.4x	n/a	CN¥6.5b
300267 Hunan Er-Kang Pharmaceutical	5.2x	n/a	CN¥6.2b

Price-To-Sales vs Peers: 300267 is good value based on its Price-To-Sales Ratio (5.2x) compared to the peer average (11.6x).

Price to Sales Ratio vs Industry

How does 300267's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$758.59m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$399.55m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 300267 is expensive based on its Price-To-Sales Ratio (5.2x) compared to the CN Pharmaceuticals industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 300267's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300267 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300267's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%